FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drugs are most likely to win approval in 12-24 months, with mechanism, trial results, approval

FDA/EMA drug approval probability + PDUFA calendar for a disease area — which Phase 3 drugs are most likely to win approval in 12-24 months, with mechanism, trial results, approval-probability scores and historical phase-3 success rates. Worldwide. For biotech-investing and payer agents.

price-ascending: candidates are ordered by the listed price of the operation, with no managed-first preference applied. Unlike /v1/apis, this surface does not rank Apiosk-settled listings above federated ones — a comparison that reorders on commercial grounds is not a comparison. Pass sort=managed_first for the catalog's ordering.

Compared: listed price, settlement rail and input compatibility. Not measured yet: latency, reliability, result quality, and provider terms such as rate limits, jurisdiction and licensing.